-
Acta Oto-laryngologica. Supplementum 1982
Comparative Study
Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Auditory Threshold; Dibekacin; Ear, Inner; Gentamicins; Guinea Pigs; Hair Cells, Auditory; Kanamycin; Tobramycin; Vestibule, Labyrinth
PubMed: 6299052
DOI: 10.3109/00016488209108895 -
La Nouvelle Presse Medicale Nov 1982During an open multicentric trial (17 centers), we have treated 62 septicemia by dibekacin, alone or associated with other antibacterial drugs. Taking into account the...
During an open multicentric trial (17 centers), we have treated 62 septicemia by dibekacin, alone or associated with other antibacterial drugs. Taking into account the degree of severity of these patients, the results are considered satisfactory in 47 patients. 15 failures were noted (including 9 deaths). General and local tolerance were good, in spite of the duration of treatment.
Topics: Adult; Aged; Anti-Bacterial Agents; Dibekacin; Drug Therapy, Combination; Female; Humans; Kanamycin; Male; Middle Aged; Sepsis
PubMed: 7155854
DOI: No ID Found -
Antimicrobial Agents and Chemotherapy Aug 1983We have developed a homogeneous substrate-labeled fluorescent immunoassay for the measurement of dibekacin concentrations in serum and plasma. The fluorogenic enzyme...
We have developed a homogeneous substrate-labeled fluorescent immunoassay for the measurement of dibekacin concentrations in serum and plasma. The fluorogenic enzyme substrate beta-galactosyl-umbelliferone was covalently attached to tobramycin, an aminoglycoside structurally similar to dibekacin, to prepare a fluorogenic drug reagent (FDR). The FDR is nonfluorescent under assay conditions, but fluoresces upon hydrolysis by beta-galactosidase. However, binding of the FDR by antiserum to the cross-reactive drug kanamycin prevents enzyme hydrolysis. The fixed level of FDR competes with dibekacin within the sample for the limiting number of antibody-binding sites in the reaction mixture. Unbound FDR is hydrolyzed by beta-galactosidase to release a fluorescent product that is proportional to the dibekacin concentration in the sample. The assay exhibits good precision, standard curve reproducibility, recovery, sensitivity, and correlation with a comparative method. Additionally, the substrate-labeled fluorescent immunoassay is rapid and easy to perform.
Topics: Binding Sites, Antibody; Dibekacin; Fluorescent Antibody Technique; Humans; Kanamycin
PubMed: 6357071
DOI: 10.1128/AAC.24.2.240 -
The Journal of Antimicrobial... Apr 1982
Comparative Study
Topics: Animals; Anti-Bacterial Agents; Creatinine; Dibekacin; Gentamicins; Kanamycin; Kidney; Male; Rats; Rats, Inbred Strains; Tobramycin
PubMed: 7085532
DOI: 10.1093/jac/9.4.297 -
Hinyokika Kiyo. Acta Urologica Japonica Aug 1983Clinical studies were performed on combination chemotherapy with Fosfomycin and Dibekacin. Sixteen patients with complicated urinary tract infections were treated with a...
Clinical studies were performed on combination chemotherapy with Fosfomycin and Dibekacin. Sixteen patients with complicated urinary tract infections were treated with a combination of Fosfomycin (4 g/day, d.i.v.) and Dibekacin (200 mg/day, i.m.) for 5 days; and, 15 of them were clinically evaluated by criteria of UTI committee. The clinical effects proved excellent in 3 patients, good in 8 patients, and poor in 4 patients overall effective rate was 73.3%. Out of 19 strains isolated from the patients, 12 strains disappeared after the therapy. No side effect was observed in 16 cases. Clinical use of the combination chemotherapy with Fosfomycin and Dibekacin was thought to be effective and safe for patients with complicated urinary tract infections, because the combination acts not only synergistically, but also because Fosfomycin acts to protect against the nephrotoxicity induced by Dibekacin.
Topics: Adult; Aged; Anti-Bacterial Agents; Dibekacin; Drug Therapy, Combination; Female; Fosfomycin; Humans; Kanamycin; Male; Middle Aged; Urinary Tract Infections
PubMed: 6675445
DOI: No ID Found -
The Japanese Journal of Antibiotics Sep 1977Pharmacokinetic behavior of dibekacin after intramuscular administration was studied in nine healthy volunteers by cross over administrations of three dosage levels (1...
Pharmacokinetic behavior of dibekacin after intramuscular administration was studied in nine healthy volunteers by cross over administrations of three dosage levels (1 mg(pot.)/kg, 1.5 mg(pot.)/kg and 2 mg(pot.)/kg). Drug concentrations in serum and urinary recoveries were measured and those data were analysed pharmacokinetically. The serum levels of this drug were in proportion to dosage, and the pharmacokinetic parameters were almost the same through the three dosage levels. Then it was considered that the pharmacokinetic behaviors of dibekacin were almost the same within the range of these dosage levels. No significant difference was found between the body clearances calculated from the data of serum levels, and the renal clearances calculated from the data of urinary recovery and serum levels. Therefore it is considered that the elimination of the drug from blood is almost due to renal excretion.
Topics: Adult; Dibekacin; Humans; Injections, Intramuscular; Kanamycin; Kinetics; Male; Metabolic Clearance Rate
PubMed: 916185
DOI: No ID Found -
The Journal of Antimicrobial... Nov 1985Thirty strains of Enterobacteriaceae and ten strains of Pseudomonas aeruginosa were selected to study the in-vitro activity of various combinations containing...
Interaction of gentamicin, dibekacin, netilmicin and amikacin with various penicillins, cephalosporins, minocycline and new fluoro-quinolones against Enterobacteriaceae and Pseudomonas aeruginosa.
Thirty strains of Enterobacteriaceae and ten strains of Pseudomonas aeruginosa were selected to study the in-vitro activity of various combinations containing aminoglycosides, by the checkerboard method. The following aminoglycosides: gentamicin, dibekacin, netilmicin and amikacin were used in combination with each of the following: ampicillin, ticarcillin, piperacillin, cefazolin, cefuroxime, ceftazidime, norfloxacin, enoxacin and minocycline. Synergy was not a constant feature of beta-lactam+aminoglycoside combinations. Discrepancies occurred with the same strain submitted to combinations containing different aminoglycosides. The combinations containing new quinolones+aminoglycosides were usually additive, although occasionally synergy occurred. The combination minocycline+aminoglycoside was usually additive but partial antagonism (FIC or FBC index: 1 X 5- less than 2) occurred in 10 to 40% of the strains depending on the aminoglycoside. The combinations of beta-lactams with dibekacin or netilmicin most frequently produced partial or full synergy against strains of Ps. aeruginosa susceptible to all four aminoglycosides tested.
Topics: Amikacin; Aminoglycosides; Anti-Bacterial Agents; Cephalosporins; Dibekacin; Drug Interactions; Enterobacteriaceae; Gentamicins; Microbial Sensitivity Tests; Netilmicin; Penicillins; Pseudomonas aeruginosa; Quinolines
PubMed: 3935637
DOI: 10.1093/jac/16.5.581 -
Chemotherapy 1990Nine aminoglycoside antibiotics, ribostamycin (RSM), dactimicin (DAC), dibekacin (DKB), kanamycin (KM), amikacin (AMK), netilmicin (NTL), tobramycin (TOB), gentamicin... (Comparative Study)
Comparative Study
Nine aminoglycoside antibiotics, ribostamycin (RSM), dactimicin (DAC), dibekacin (DKB), kanamycin (KM), amikacin (AMK), netilmicin (NTL), tobramycin (TOB), gentamicin (GM) and sisomicin (SISO) were administered intramuscularly to guinea pigs for 4 weeks, and ototoxicity and drug concentration in the inner ear fluid were determined. RSM and DAC showed the weakest ototoxicity against the cochlea and vestibular organs. AMK and KM were more toxic to cochlea than vestibular organs. DKB, TOM, GM and SISO were equally toxic to vestibular organs and cochlea. NTL was more toxic to vestibular organs than cochlea. As judged from the pinna reflex response and hair cell damage in the cochlea, the order of auditory toxicity was the following: SISO greater than GM greater than TOB greater than AMK greater than DKB greater than KM greater than NTL, DAC RSM, whereas the vestibular toxicity was in the following order: SISO greater than GM greater than DKB greater than TOB greater than NTL greater than AMK greater than KM greater than DAC, RSM. RSM, causing the weakest ototoxicity, showed a low drug concentration in the inner ear fluid, while GM, causing severe ototoxicity, showed the highest drug level under the same conditions.
Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Cochlea; Ear, Inner; Guinea Pigs; Hair Cells, Auditory; Injections, Intramuscular; Male; Perilymph; Reflex, Abnormal; Time Factors
PubMed: 2311443
DOI: 10.1159/000238762 -
La Nouvelle Presse Medicale Nov 1982Thirty six patients in an intensive care unit with a bacterial bronchopulmonary infection were treated with intraparenteral dibekacin at a dose of 3 mg/kg/day. Mean age...
Thirty six patients in an intensive care unit with a bacterial bronchopulmonary infection were treated with intraparenteral dibekacin at a dose of 3 mg/kg/day. Mean age of the patients was 55 years and the mean duration of treatment 14 days. Biological material was obtained by fibro-aspiration or pleural tap. One or more organisms were identified in 36 cases. These were essentially staphylococci and Gram negative bacilli sensitive to dibekacin. Results showed a favourable course in 26 cases and a clinical improvement in 10. Clinical and biological tolerance was good. No clinical manifestations of cochleo-vestibular toxicity were seen.
Topics: Adult; Aged; Bacterial Infections; Dibekacin; Female; Humans; Intensive Care Units; Kanamycin; Lung Diseases; Male; Middle Aged
PubMed: 7155856
DOI: No ID Found -
Clinical Pharmacology : Advances and... 2014Arbekacin sulfate (ABK), an aminoglycoside antibiotic, was discovered in 1972 and was derived from dibekacin to stabilize many common aminoglycoside modifying enzymes.... (Review)
Review
Arbekacin sulfate (ABK), an aminoglycoside antibiotic, was discovered in 1972 and was derived from dibekacin to stabilize many common aminoglycoside modifying enzymes. ABK shows broad antimicrobial activities against not only Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) but also Gram-negative bacteria such as Escherichia coli, Pseudomonas aeruginosa, and Klebsiella pneumoniae. ABK has been approved as an injectable formulation in Japan since 1990, under the trade name Habekacin, for the treatment of patients with pneumonia and sepsis caused by MRSA. The drug has been used in more than 250,000 patients, and its clinical benefit and safety have been proven over two decades. ABK currently shows promise for the application for the treatment of multidrug-resistant Gram-negative bacterial infections such as multidrug-resistant strains of P. aeruginosa and Acinetobacter baumannii because of its synergistic effect in combination with beta-lactams.
PubMed: 25298740
DOI: 10.2147/CPAA.S44377